Agomelatine augmentation of sertraline in the treatment of moderate to severe obsessive-compulsive disorder: a randomized double-blinded placebo-controlled clinical trial

BACKGROUND: As 40–60% of the patients with obsessive-compulsive disorder (OCD) do not adequately respond to the first-line treatment, finding an effective second-line treatment is required. Our aim was to assess the efficacy and safety of agomelatine (a selective melatonin receptor agonist and a 5-h...

Descripción completa

Detalles Bibliográficos
Autores principales: Shokrani, Marjan, Askari, Sanaz, Eissazade, Negin, Shariat, Seyed Vahid, Shariati, Behnam, Yarahmadi, Masoomeh, Shalbafan, Mohammadreza
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10512611/
https://www.ncbi.nlm.nih.gov/pubmed/37735631
http://dx.doi.org/10.1186/s12888-023-05189-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10512611/
https://www.ncbi.nlm.nih.gov/pubmed/37735631
http://dx.doi.org/10.1186/s12888-023-05189-7

Ejemplares similares